This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
Recommended interval between AstraZeneca vaccine doses in outbreak situations
On 13 July, ATAGI released a statement which recommends that in outbreak situations, a shorter interval of 4 to 8 weeks is preferred between the first and second doses of COVID-19 Vaccine AstraZeneca. Shortening the gap between first and second doses will bring forward short term protection, which is expected to be beneficial in outbreak situations.
In non-outbreak settings, the preferred interval between doses of COVID-19 Vaccine AstraZeneca remains at 12 weeks.
Who is eligible to receive the Pfizer COVID-19 vaccine?
The following people are currently eligible for the Pfizer vaccine:
This new clinical guideline for health professions outlines the primary care approach to identifying, diagnosing and treating thrombosis with thrombocytopenia syndrome (TTS) after COVID-19 AstraZeneca vaccine.
Key messages
Primary health care providers should consider the potential for a patient having TTS if they present with possible thrombosis or thrombocytopenia 4-42 days after they have received a dose of the AstraZeneca vaccine.
Suspected cases should be immediately referred to an emergency department if they are acutely unwell (for example, they have a neurological deficit).
Prioritisation of residential aged care workers is particularly important given it will be mandatory for all aged care workers to have received a minimum first dose COVID-19 vaccine by 17 September as a condition of employment.
Vaccination sites are requested to facilitate access to a vaccine booking (with AstraZeneca or Pfizer if available) withintwo weeks upon receiving a request from an aged care worker where possible. All aged care workers, regardless of age, can access the Pfizer vaccine.
Home visits for patients who cannot attend a clinic
Both the Pfizer and AstraZeneca COVID-19 vaccines are in multi-dose vials. This may make it challenging to administer vaccines off-site such as for home visits, or at residential aged care or disability accommodation facilities. The following advicehas been provided for vaccine providers for administering COVID-19 vaccines off-site:
transport the vial and draw up the dose at the site of administration. For the Pfizer vaccine, you can either dilute the vaccine in your practice or at the site of administration
transport pre-drawn doses if you can appropriately store the vaccine and deliver it promptly. This means protecting the vaccine from light and maintaining appropriate cold chain. This also means delivering the vaccine within one hour if kept at room temperature, or six hours if stored at 2-8°C. If you cannot ensure these conditions, you should transport the vial and draw up the dose on site.
You must ensure that each vial or dose is stored at the recommended temperature and does not exceed the total maximum storage period specified in the Product Information. See AstraZeneca product information and Pfizer product information. ATAGI recommends that, when possible, pre-drawn doses kept at room temperature be used within an hour to minimise any remote potential risk of infection. See Transporting, storing and handling vaccines p20
MBS item numbers that can be claimed for COVID-19 vaccination home visits:
90005 Flag fall service Fee: $67.35 Benefit: 85% = $57.25
The ATAGI clinical statement provides recommendations for the two zoster vaccines now available for use, Zostavax and Shingrix.
Shingrix is preferred over Zostavax from age 50 years and above for prevention of herpes zoster and its complications, due to its higher efficacy. However, availability is expected to be limited, and it needs to be privately prescribed.
Zostavax remains a readily available and effective alternative vaccine for immunocompetent adults aged ≥50 years who wish to reduce their risk of herpes zoster. It is recommended and funded under the National Immunisation Program (NIP) for immunocompetent people aged 70 years of age (with catch-up for those aged 71-79 years until October 2021).
Where to report a cold chain breach
Cold chain breach of all COVID-19 vaccines should be reported to the Vaccine Operations Centre (VOC) on 1800 318 208. VOC hours of operation are from 7am to 10pm AEST, or email COVID19VaccineOperationsCentre@Health.gov.au.
Cold chain breach of National Immunisation Program (NIP) vaccines should be reported to the Public Health Unit (PHU). Fill out the Cold chain breach and vaccine wastage reporting form and submit to PHU along with data logger report and temperature chart.
For privately purchased vaccines, contact the vaccine manufacturer for further advice following a cold chain breach.
Mandatory reporting of all nip vaccines
From 1 July 2021, vaccination providers are required to report all National Immunisation Program (NIP) vaccines administered to the Australian Immunisation Register (AIR) within 24 hours, and no more than 10 working days after the vaccination.
Health professionals should use the latest version of their clinical software to make sure they meet reporting requirements.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Launch of new Australian Guideline for assessing and managing cardiovascular disease risk The 2023 Australian Guideline for assessing and managing cardiovascular disease risk, and associated Australian cardiovascular disease risk calculator (Aus CVD Risk Calculator), will become the new standard of care for the primary prevention of CVD in Australia. This…
At CESPHN we value your feedback and invite you to complete the 2023 stakeholder engagement survey At CESPHN, we value your feedback and invite you to complete the stakeholder engagement survey on our service delivery and communication over the past 12 months. This short survey only takes five minutes and…
CESPHN Healthy Ageing Strategy 2023-28 has been released The Central and Eastern Sydney PHN has developed a Healthy Ageing Strategy to empower older people in our region to live more active and fulfilling lives, enabled by inclusive communities, and supported by integrated person-centred health and social services. Healthy ageing relies…
NSW community urged to be on alert amid rise in listeriosis NSW Health is reminding people who are immunocompromised, pregnant, or aged over 65 years to avoid foods that can cause listeriosis, following several confirmed cases of listeria infection in NSW. Listeriosis infection, which comes from consuming food contaminated with…
CESPHN Primary Health Awards: 2023 Finalists and Winners announced At a packed event last night at the Hazelhurst Arts Centre in Gymea, CESPHN held its annual Primary Health Awards. CESPHN’s multicultural community was reflected in our numerous and diverse submissions. All immensely impressive. The winners, announced at the awards event,…